All Other, Including Affiliated Entity was Inovio Pharmaceuticals’s largest revenue line in fiscal 2023, bringing in $586.95K of $832.01K (71%).
| Customer | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 |
|---|---|---|---|---|---|---|---|---|
| Apollobio | — | — | — | — | ||||
| Darpa | — | — | — | — | ||||
| Roche | — | — | — | — | ||||
| U.S. Department Of Defense | — | $754.85K | $9.59M | — | ||||
| Astrazeneca | — | — | — | — | ||||
| Advaccine | $5.00M | — | — | — | ||||
| All Other, Including Affiliated Entity | — | — | — | $586.95K | ||||
| All Other, Including Affiliated Entities | $1.04M | $774.60K | $636.89K | — | ||||
| All Other | — | — | — | — | ||||
| Geneone (Affiliated Entity) | — | — | — | — | ||||
| Plumbline Life Sciences, Inc. (Affiliated Entity) | $1.37M | $245.31K | $33.60K | — | ||||
| Apollobio Corporation | — | — | — | $245.06K | ||||
| Total | $7.41M | $1.77M | $10.26M | $832.01K |
Inovio Pharmaceuticals brought in $832.01K from its two revenue lines in fiscal 2023, the year ended December 31, 2023. Inovio Pharmaceuticals regrouped these revenue lines after fiscal 2022, so the total does not compare directly with that year's $10.26M. All Other, Including Affiliated Entity was the largest at $586.95K (70.5%), ahead of Apollobio Corporation at $245.06K (29.5%).
Inovio Pharmaceuticals began breaking out All Other, Including Affiliated Entity in fiscal 2023 and Apollobio Corporation in fiscal 2023. Inovio Pharmaceuticals stopped reporting U.S. Department Of Defense ($9.59M in fiscal 2022), Advaccine ($5.00M in fiscal 2020), All Other, Including Affiliated Entities ($636.89K in fiscal 2022) and one other as separate revenue lines.
Other Revenue From Affiliated Entities was Inovio Pharmaceuticals’s largest product and service line in fiscal 2020, bringing in $111.00K of $236.18K (47%).
| Product and Service | FY 2016 | FY 2017 | FY 2017 | FY 2017 | FY 2017 | FY 2018 | FY 2018 | FY 2018 | FY 2018 | FY 2019 | FY 2019 | FY 2019 | FY 2019 | FY 2020 | FY 2020 | FY 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grants & Miscellaneous Revenue | $5.24M | $2.80M | $1.46M | — | — | — | — | — | — | — | — | — | — | — | — | |
| Revenue Under Collaborative Research & Development Arrangements | $4.29M | $16.36M | $351.27K | $28.41M | $1.29M | $24.39M | $1.81M | $29.86M | $2.77M | $64.28K | $617.43K | $3.64M | $71.50K | $74.10K | $21.49K | |
| Grants & Miscellaneous Revenue From Affiliated Entity | $614.04K | $1.08M | $707.92K | $2.57M | — | — | — | — | — | — | — | — | — | — | — | |
| Revenue Under Collaborative Research & Development Arrangements From Affiliated Entities | — | — | — | — | — | — | — | $449.52K | $55.58K | $71.39K | $53.01K | $235.65K | $1.17M | $95.15K | $103.68K | |
| Revenue Under Collaborative Research & Development Arrangements With Affiliated Entities | — | — | — | $765.83K | $148.01K | $60.32K | $184.99K | — | — | — | — | — | — | — | — | |
| Revenue Under Collaborative Research & Development Arrangements With Affiliated Entity | $233.33K | $176.88K | $129.13K | — | — | — | — | — | — | — | — | — | — | — | — | |
| Other Revenue | — | — | — | — | — | — | — | $171.59K | — | — | — | $237.54K | — | — | — | |
| Other Revenue From Affiliated Entities | — | — | — | — | — | — | — | — | $3.61K | — | $196.42K | $1.80K | $83.65K | $97.94K | $111.00K | |
| Miscellaneous Revenue, Including From Affiliated Entities | — | — | — | $10.47M | $92.59K | $2.59K | $2.59K | — | — | — | — | — | — | — | — | |
| Total | $10.38M | $20.41M | $2.64M | $42.22M | $1.53M | $24.45M | $2.00M | $30.48M | $2.83M | $135.67K | $866.86K | $4.11M | $1.33M | $267.19K | $236.18K |
Inovio Pharmaceuticals brought in $236.18K from its three product and service lines in fiscal 2020, the year ended September 30, 2020. That was down 11.6% from $267.19K in fiscal 2020. Other Revenue From Affiliated Entities was the largest at $111.00K (47.0%), ahead of Revenue Under Collaborative Research & Development Arrangements From Affiliated Entities at $103.68K (43.9%) and Revenue Under Collaborative Research & Development Arrangements at $21.49K (9.1%).
Compared with fiscal 2020, Other Revenue From Affiliated Entities grew fastest, up 13.3% to $111.00K, while Revenue Under Collaborative Research & Development Arrangements fell the most, down 71.0% to $21.49K.
Inovio Pharmaceuticals began breaking out Revenue Under Collaborative Research & Development Arrangements From Affiliated Entities in fiscal 2018 and Other Revenue From Affiliated Entities in fiscal 2019. Inovio Pharmaceuticals stopped reporting Grants & Miscellaneous Revenue From Affiliated Entity ($2.57M in fiscal 2017), Grants & Miscellaneous Revenue ($1.46M in fiscal 2017), Other Revenue ($237.54K in fiscal 2019) and three others as separate lines.
Inovio Pharmaceuticals (INO) reports its revenue by customer and by product and service. In fiscal 2023, All Other, Including Affiliated Entity was its largest revenue line, bringing in $586.95K (70.5% of the total), followed by Apollobio Corporation at $245.06K (29.5%).
All Other, Including Affiliated Entity was Inovio Pharmaceuticals' largest revenue line in fiscal 2023, bringing in $586.95K, or 70.5% of the $832.01K total across its two revenue lines.
Other Revenue From Affiliated Entities was Inovio Pharmaceuticals' largest product and service line in fiscal 2020, bringing in $111.00K, or 47.0% of the $236.18K total across its three product and service lines.
Every figure comes from Inovio Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Inovio Pharmaceuticals gives it, and years follow its fiscal calendar.
Inovio Pharmaceuticals' revenue by customer goes back to fiscal 2016, with figures through fiscal 2023. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.